Page 258 - Vitamin D and Cancer

10 Vitamin D and Prostate Cancer 245

87. Ahn J, Albanes D, Peters U et al (2007) Dairy products, calcium intake, and risk of prostate
cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol
Biomarkers Prev 16:2623–2630
88. Kristal AR, Cohen JH, Qu P et al (2002) Associations of energy, fat, calcium, and vitamin
D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 11:719–725
89. Ahonen MH, Tenkanen L, Teppo L et al (2000) Prostate cancer risk and prediagnostic serum
25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11:847–852
90. Corder EH, Guess HA, Hulka BS et al (1993) Vitamin D and prostate cancer: a prediagnostic
study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467–472
91. Li H, Stampfer MJ, Hollis JB et al (2007) A prospective study of plasma vitamin D metabolites,
vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4:e103
92. Tuohimaa P, Tenkanen L, Ahonen M et al (2004) Both high and low levels of blood vitamin
D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study
in the Nordic countries. Int J Cancer 108:104–108
93. Ahn J, Peters U, Albanes D et al (2008) Serum vitamin D concentration and prostate cancer
risk: a nested case-control study. J Natl Cancer Inst 100:796–804
94. Braun MM, Helzlsouer KJ, Hollis BW et al (1995) Prostate cancer and prediagnostic levels
of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6:
235–239
95. Faupel-Badger JM, Diaw L, Albanes D et al (2007) Lack of association between serum
levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men.
Cancer Epidemiol Biomarkers Prev 16:2784–2786
96. Gann PH, Ma J, Hennekens CH et al (1996) Circulating vitamin D metabolites in relation
to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5:
121–126
97. Jacobs ET, Giuliano AR, Martinez ME et al (2004) Plasma levels of 25-hydroxyvitamin D,
1, 25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol
89–90:533–537
98. Platz EA, Leitzmann MF, Hollis BW et al (2004) Plasma 1, 25-dihydroxy- and 25-hydroxy-
vitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15:255–265
99. Nomura AM, Stemmermann GN, Lee J et al (1998) Serum vitamin D metabolite levels and the
subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control
9:425–432
100. Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D
status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459
101. Bernardi RJ, Trump DL, Yu WD et al (2001) Combination of 1alpha, 25-dihydroxyvitamin
D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor
cross-talk and Erk/Akt signaling. Clin Cancer Res 7:4164–4173
102. Yu WD, McElwain MC, Modzelewski RA et al (1998) Enhancement of 1, 25-dihydroxyvitamin
D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 90:134–141
103. Hershberger PA, Modzelewski RA, Shurin ZR et al (1999) 1, 25-Dihydroxycholecalciferol
(1, 25–D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/
Cip1) in vitro and in vivo. Cancer Res 59:2644–2649
104. Bernardi RJ, Johnson CS, Modzelewski RA et al (2002) Antiproliferative effects of 1alpha,
25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells.
Endocrinology 143:2508–2514
105. Beer TM, Hough KM, Garzotto M et al (2001) Weekly high-dose calcitriol and docetaxel in
advanced prostate cancer. Semin Oncol 28:49–55
106. Hershberger PA, Yu WD, Modzelewski RA et al (2001) Calcitriol (1, 25-dihydroxychole-
calciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates
paclitaxel-induced apoptosis. Clin Cancer Res 7:1043–1051
107. Moffatt KA, Johannes WU, Miller GJ (1999) 1Alpha, 25dihydroxyvitamin D3 and platinum
drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res
5:695–703